Clarithromycin. A review of its pharmacological properties and therapeutic use in Mycobacterium avium-intracellulare complex infection in patients with acquired immune deficiency syndrome.
Results from noncomparative and placebo-controlled studies demonstrate the efficacy of clarithromycin in the treatment of disseminated Mycobacterium avium-intracellulare complex (MAC) infection in patients with acquired immune deficiency syndrome (AIDS). Whether given alone or in combination with other antimycobacterial treatments, doses of 500 to 2000mg (typically 1000mg) administered twice daily are effective in controlling bacteraemia in these patients. Clarithromycin has also been shown to improve clinical symptoms of infection and may improve quality of life in AIDS patients with MAC infection. Clarithromycin is generally well tolerated when used in the doses typically required for the treatment of MAC infection (1000 or 2000 mg/day). Gastrointestinal disturbances are the most commonly occurring adverse events and occur most frequently at dosages of 4000 mg/day. Thus, clarithromycin, as monotherapy or in combination with other antimycobacterial agents, is well tolerated and effectively eradicates MAC from the blood in the short term in patients with AIDS: however, short term monotherapy may lead to bacterial resistance, underscoring the importance of long term treatment with a combination of antimycobacterial agents. While the optimal combination regimen to prevent the development of resistance to antimycobacterial agents. While the optimal combination regimen to prevent the development of resistance to antimycobacterial agents by MAC remains to be determined, clarithromycin will almost certainly be a valuable agent in any such combination.
Barradell
L B
LB
Adis International Limited, Auckland, New Zealand.
Plosker
G L
GL
McTavish
D
D
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications*; D000818:Animals; D017291:Clarithromycin / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D004334:Drug Administration Schedule; D004347:Drug Interactions; D004359:Drug Therapy, Combination / Q000627:therapeutic use; D004361:Drug Tolerance; D006801:Humans; D008826:Microbial Sensitivity Tests; D009162:Mycobacterium avium / Q000187:drug effects; D015270:Mycobacterium avium-intracellulare Infection / Q000150:complications / Q000188:drug therapy*; D014376:Tuberculosis / Q000188:drug therapy / Q000662:veterinary
D017291:Clarithromycin